In last trading session, Outlook Therapeutics Inc. (NASDAQ:OTLK) saw 1.33 million shares changing hands with its beta currently measuring 0.86. Company’s recent per share price level of $1.30 trading at $0.05 or 4.00% at ring of the bell on the day assigns it a market valuation of $303.12M. That closing price of OTLK’s stock is at a discount of -227.69% from its 52-week high price of $4.26 and is indicating a premium of 28.46% from its 52-week low price of $0.93. Taking a look at company’s average trading volume of 1.40 million if we extend that period to 3-months.
For Outlook Therapeutics Inc. (OTLK), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.06 in the current quarter.
Outlook Therapeutics Inc. (NASDAQ:OTLK) trade information
Upright in the green during last session for gaining 4.00%, in the last five days OTLK remained trading in the red while hitting it’s week-highest on Thursday, 01/13/22 when the stock touched $1.30 price level, adding 3.7% to its value on the day. Outlook Therapeutics Inc.’s shares saw a change of -4.41% in year-to-date performance and have moved -0.76% in past 5-day. Outlook Therapeutics Inc. (NASDAQ:OTLK) showed a performance of -6.47% in past 30-days.
Wall Street analysts have assigned a consensus price target of $6.63 to the stock, which implies a rise of 80.39% to its current value. Analysts have been projecting $6.00 as a low price target for the stock while placing it at a high target of $7.25. It follows that stock’s current price would drop -457.69% in reaching the projected high whereas dropping to the targeted low would mean a loss of -361.54% for stock’s current value.
Outlook Therapeutics Inc. (OTLK) estimates and forecasts
Statistics highlight that Outlook Therapeutics Inc. is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -41.96% of value to its shares in past 6 months, showing an annual growth rate of 17.14% while that of industry is 7.90. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to increase by 50.00% in the current quarter and calculating 33.30% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 58.80% during past 5 years.
Outlook Therapeutics Inc. is more likely to be releasing its next quarterly report between February 14 and February 18 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Outlook Therapeutics Inc. (NASDAQ:OTLK)’s Major holders
Insiders are in possession of 45.09% of company’s total shares while institution are holding 10.66 percent of that, with stock having share float percentage of 19.41%. Investors also watch the number of corporate investors in a company very closely, which is 10.66% institutions for Outlook Therapeutics Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at OTLK for having 5.84 million shares of worth $12.67 million. And as of Sep 29, 2021, it was holding 2.60% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group, Inc. (The), which was holding about 4.74 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 2.11% of outstanding shares, having a total worth of $10.29 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2021, the former fund manager was holding 2.69 million shares of worth $5.84 million or 1.20% of the total outstanding shares. The later fund manager was in possession of 2.04 million shares on Oct 30, 2021, making its stake of worth around $4.23 million in the company or a holder of 0.91% of company’s stock.